Happy Return? Teva Saying No to 'De-risked' Rexahn Therapy
By Randy Osborne
Thursday, August 29, 2013
Rexahn Pharmaceuticals Inc. is going ahead with development of RX-3117 after Teva Pharmaceutical Industries Ltd. declined its option to continue with the cancer therapy, which proved orally bioavailable with no adverse events in a small, European Phase I trial.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.